


Appl. No.: 10/528,444  
Amendment Dated October 18, 2005

Attorney Docket No. 58260-011600

### CLAIMS

**Claim 1 (currently amended):** A triptolide derivative of formula I




I

wherein R1 is [[H,]] phosphate ( $-\text{P}(\text{O})(\text{Ox}_1)(\text{Ox}_2)$ ), or phosphite ( $-\text{P}(\text{H})(\text{Ox}_1)(\text{Ox}_2)$ ), and X<sub>1</sub> and X<sub>2</sub> are Na, K, or NH<sub>4</sub>.

**Claim 2 (original):** A method for preparation of the compound according to claim 1, comprising the step of reacting the first lead compound triptolide with POCl<sub>3</sub>, PCl<sub>3</sub> or other phosphonate halide, phosphate, phosphite halide, phosphite.

**Claim 3 (currently amended):** A triptolide derivative of formula II



II

**BEST AVAILABLE COPY**



Appl. No.: 10/528,444  
Amendment Dated October 18, 2005

Attorney Docket No. 58260-011600

**Claim 7 (currently amended):** The compound of claim 5 wherein said compound is used ~~Use of the compounds according to any one of claims 1, 3, and 5~~ in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent.


**Claim 8 (original):** The use according to claim 7, wherein said immunosuppressive agent or anti-inflammatory agent is used in the treatment of diseases associated with growth of lymphocytes T and B cells; production of cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2.

**Claim 9 (original):** The use according to Claim 8, wherein said diseases are autoimmune deficiency diseases and inflammatory diseases.

**Claim 10 (original):** The use according to claim 9, wherein said diseases are selected from the group consisted of rheumatoid arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

**Claim 11 (original):** The use according to claim 7, wherein said immunosuppressive agent or anti-inflammatory agent is used in the prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation.

**Claim 12 (new):** A triptolide derivative of formula IIIb



IIIb

wherein R<sub>2</sub> is H, SCN, Cl or Br.

Appl. No.: 10/528,444  
Amendment Dated October 18, 2005

Attorney Docket No. 58260-011600

**Claim 13 (new):** A method for preparation of the compound according to claim 12, comprising the step of reacting the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with  $\text{POCl}_3$  or other phosphonate halide, phosphate, phosphite and the like, or the step of reacting the first lead compound triptolide with  $\text{POCl}_3$  or other phosphonate halide, phosphite halide and the like.

**Claim 14 (new):** The compound of Claim 12 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent.

**Claim 15 (new):** The use according to claim 14, wherein said immunosuppressive agent or anti-inflammatory agent is used in the treatment of diseases associated with growth of lymphocytes T and B cells; production of cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2.

**Claim 16 (new):** The use according to claim 15, wherein said diseases are autoimmune deficiency diseases and inflammatory diseases.

**Claim 17 (new):** The use according to claim 16, wherein said diseases are selected from the group consisted of rheumatoid arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

**Claim 18 (new):** The use according to claim 14, wherein said immunosuppressive agent or anti-inflammatory agent is used in the prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation.

**Claim 19 (new):** The compound of Claim 3 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent.

**Claim 20 (new):** The use according to claim 19, wherein said immunosuppressive agent or anti-inflammatory agent is used in the treatment of diseases associated with growth of lymphocytes T and B cells; production of cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2.

Appl. No.: 10/528,444  
Amendment Dated October 18, 2005

Attorney Docket No. 58260-011600

**Claim 21 (new):** The use according to claim 20, wherein said diseases are autoimmune deficiency diseases and inflammatory diseases.

**Claim 22 (new):** The use according to claim 21, wherein said diseases are selected from the group consisted of rheumatoid arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

**Claim 23 (new):** The use according to claim 19, wherein said immunosuppressive agent or anti-inflammatory agent is used in the prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation.

**Claim 24 (new):** The compound of Claim 1 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent.

**Claim 25 (new):** The use according to claim 24, wherein said immunosuppressive agent or anti-inflammatory agent is used in the treatment of diseases associated with growth of lymphocytes T and B cells; production of cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2.

**Claim 26 (new):** The use according to claim 25, wherein said diseases are autoimmune deficiency diseases and inflammatory diseases.

**Claim 27 (new):** The use according to claim 26, wherein said diseases are selected from the group consisted of rheumatoid arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

**Claim 28 (new):** The use according to claim 24, wherein said immunosuppressive agent or anti-inflammatory agent is used in the prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation.

**Claim 29 (new):** The compound according to Claim 3 wherein  $R_1$  is one of a phosphate ( $-\text{P}(\text{O})(\text{O}X_1)(\text{O}X_2)-$ ) or a phosphite ( $-\text{P}(\text{H})(\text{O}X_1)(\text{O}X_2)-$ ) and wherein  $X_1$  and  $X_2$  are Na or K or  $\text{NH}_4$  and  $R_2$  is H or SCN or Cl or Br.

Appl. No.: 10/528,444  
Amendment Dated October 18, 2005

Attorney Docket No. 58260-011600

**Claim 30 (new):** The compound of Claim 29 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent.

**Claim 31 (new):** The use according to claim 30, wherein said immunosuppressive agent or anti-inflammatory agent is used in the treatment of diseases associated with growth of lymphocytes T and B cells; production of cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2.

**Claim 32 (new):** The use according to claim 31, wherein said diseases are autoimmune deficiency diseases and inflammatory diseases.

**Claim 33 (new):** The use according to claim 32, wherein said diseases are selected from the group consisted of rheumatoid arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

**Claim 34 (new):** The use according to claim 30, wherein said immunosuppressive agent or anti-inflammatory agent is used in the prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation.

**Claim 35 (new):** A method for preparation of the compound according to claim 5, comprising the step of reacting the first lead compound triptolide with  $\text{POCl}_3$ , or other phosphonate halide, phosphate halide and the like.

**Claim 36 (new):** A method for preparation of the compound according to claim 3, comprising the step of phosphoric esterifying the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with  $\text{POCl}_3$ ,  $\text{PCl}_3$ , phosphonate halide, phosphate, phosphite halide, or phosphate to obtain the compound of formula II.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**